Phase Diagnostics’ focus is to develop next generation rapid point-of-care diagnostics for major unmet needs. Our platform technology enables unprecedented point-of-care accuracy for an array of potential applications, offering solutions for clinical, food safety manufacturing, and consumer diagnostic demands.
Phase Diagnostics is developing handheld, one-step, rapid point-of-care devices for the detection of various biomarkers. Our proprietary technology combines the ease-of-use and very low cost of rapid point-of-care diagnostics with the very high accuracy of lab-based tests, offering the best of both worlds.
Phase Diagnostics aims to offer a broad range of rapid diagnostic testing kits that can detect various analytes of interest (i.e. viruses, bacteria, proteins, etc.). To do this, Phase Diagnostics’ devices leverage the company’s 3PS (3-Dimensional Paper Sensors) technology, a patented detection system that combines the following two steps:
By performing these two steps in sequence, our system effectively lowers the detection threshold of existing LFA tests by 10-1000 fold. Furthermore, since both steps take between 5-10 minutes, the entire test can easily be run in less than 20 minutes.
Separation of biomolecules using aqueous two-phase systems (ATPS) was initially described by scientists over 40 years ago and is used extensively today in various biochemical and cell biologic applications. Laws of thermodynamics dictate that a mixture of certain chemical compositions in an aqueous solution separate into two phases. These two phases vary in the degree of their hydrophobicity, thus biomolecules suspended in such a mixture tend to partition into one of the two phases based on their physiochemical properties (hydrophilic molecules partition to the hydrophilic phase).
ATPS has many advantages over traditional organic solvent-based extraction techniques. For example, ATPS forms a gentle environment for biomolecules and thus acts to stabilize their structures and preserve their biological activities. This is extremely important, since denatured biomolecules are poorly recognized by antibodies and therefore are not substrates for further quantification/purification.
The basic LFA strip consists of a linearly arranged sample pad, conjugate pad, nitrocellulose membrane, and absorption pad. During testing, a sample is added to the proximal end of the strip (the sample pad). Here the sample is processed to make it compatible with the remainder of the test. After treatment, the sample migrates to the conjugate pad where antigens in the sample encounter and interact with immobilized particulate conjugates. The conjugates are typically a colloid gold or latex particle to which either an antigen or antibody has been affixed (depending on the format of the assay). The analyte in the sample interacts with the conjugate particles, after which both migrate in complex to the nitrocellulose membrane. As the sample reaches the reaction portion of the nitrocellulose membrane, it encounters a complementary component (either antibody or antigen) with which the conjugated particles can interact only via the presence of the analyte (the presence of which the assay is testing for). A positive result causes a buildup of conjugated particles at the test line, which is interpreted by the presence or absence of a line, read by the naked eye.
Dr. Ricky Chiu is the co-founder and CEO of Phase Diagnostics. He is the lead inventor of Phase Diagnostics’ platform technology, which was based on his Ph.D. work. He was formerly at BMC (acquired by Alere Inc.,) where he took several rapid POC diagnostics from concept to market. Dr. Chiu received his PhD in bioengineering at the University of California, Los Angeles.
Garrett Mosley co-founded Phase Diagnostics while working towards his doctoral degree in Bioengineering under the direction of Dr. Daniel Kamei. He received his bachelor’s degree in Biochemistry and Psychology at California Lutheran University.
Felix Chao is the Director of Operations at Phase Diagnostics. He was the former Head of Project Management at SciClone Pharmaceuticals, a global spec-pharma company with revenues over $150 million. He received his B.S. in Bioengineering from the University of California, Los Angeles.
Dr. Byron Kwan is the Director of Innovation at Phase Diagnostics. He received his Ph.D. in Biological Engineering from the Massachusetts Institute of Technology under the direction of Professor K. Dane Wittrup (co-founder of Adimab) and his B.S. in Bioengineering from the University of California, Los Angeles.
Brian Lee is a Research Associate at Phase Diagnostics. He was a former process engineer at Baxalta where he supported manufacturing and capital projects. Brian received his M.S. and B.S. in bioengineering at the University of California, Los Angeles.
Beatrice Lim is a Research Associate at Phase Diagnostics. She received her M.S. in physiology and biophysics from Georgetown University and her B.S. in biological sciences and B.A. in psychology from the University of California, Irvine.
Dr. Ben Wu is the Chair and Professor in the Department of Bioengineering at UCLA with joint academic appointments in the Department of Materials Science and Engineering and the School of Dentistry. Dr. Wu is a co-founder of multiple startups and is on the scientific advisory boards of 4 other companies, providing expertise on biomaterials processing, characterization, and clinical usage.
Dr. Daniel Kamei is the Vice Chair and Associate Professor in the UCLA Department of Bioengineering. His research in aqueous two-phase complex fluid systems and their combination with the lateral-flow immunoassay has led to multiple peer-reviewed publications that have significantly impacted the development of the Phase Diagnostics platform technology.
|Address||10527 Garden Grove Blvd, Garden Grove, CA, 92843|
|Phone||+1 (714) 884-3861|